Allergen immunotherapy (AIT) is the only disease-modifying treatment option for patients with IgE-mediated inhalant allergies. Though used in clinical practice for more than 100 years, most innovations in AIT efficacy and safety have been developed in the last two decades. This expert review aimed to highlight the recent progress in AIT for both application routes, the sublingual (SLIT) and subcutaneous (SCIT) forms. As such, it covers recent aspects regarding efficacy and safety in clinical trials and real-life data and outlines new concepts in consensus and position papers as well as in guidelines for AIT. Potential clinical and nonclinical biomarkers are discussed. This review also focuses on potential future perspectives in AIT, such as alternative application routes, immune-modulating adjuvants, and recombinant vaccines. In conclusion, this state of the art review provides a comprehensive overview of AIT and highlights unmet needs for the future.
other; however, because allergen products are available in many countries across the globe, their regulation is very heterogeneous. 10 In general, AIT vaccines are classified as medicinal products in most countries and therefore require marketing authorization similar to other medicinal products. [10] [11] [12] Allergen standardization (AS) by measuring potency ensures consistency in the composition of products and demonstrates the stability of the preparation, which is a prerequisite for providing reagents for AIT products. 11, 12 In this regard, molecular technologies have accelerated the characterization of allergen preparations, providing for the discrimination of optimal reagents for advanced AS. 13 Different guidelines for AIT are internationally published but are heterogeneous regarding their methodological quality. 14 In routine use, AIT is performed through the subcutaneous (SCIT) or sublingual route (SLIT), and a treatment course of 3 years is recommended to achieve long-term efficacy. [15] [16] [17] [18] Direct comparisons between SCIT and SLIT regarding their clinical efficacies are scant. Durham and Penagos performed a subgroup analysis of the efficacy of AIT based on Cochrane databases. 19 Although an indirect comparison indicated clinical benefit of SCIT was superior than SLIT in this analysis, the overall balance of efficacy and tolerability suggests an equipoise of the application routes. 19 No significant differences could be found in a network meta-analysis of commercialized SCIT and SLIT products. 20 Conventional SCIT is associated with some disadvantages, such as the need for frequent injections, the need for visits to a practice/ hospital, and the potential risk for adverse events involving lifethreatening anaphylaxis in very rare cases. 21 Due to its good tolerability in general, SLIT allows self-administration at home without the supervision of a physician. 22 However, SLIT requires daily administration, which may affect patient adherence to the treatment. Several sublingual formulations, which are available mainly as liquid drops and tablet preparations, have been widely used. As for SCIT, there is a high amount of heterogeneity between products for SLIT, for example, the allergen contents in the products are not fully standardized with different units, such as the allergy unit native (AUN), bioequivalent allergy unit (BAU), index of reactivity (IR), standardized quality (SQ), and standardized qualitytablet (SQ-T). 23 Moreover, the optimal dose for SLIT is associated with a number of patient-and product-specific factors. 24 Indeed, a recent review assessed studies of various SLIT formulations and determined that effective doses of major allergens ranged from 1.68 μg to 84 μg of allergen. 
| EFFICACY AN D SAFETY OF AIT
A high degree of evidence exists for the efficacy of AIT in different indications 27-31 also see below. However, all meta-analyses also demonstrate a high grade of heterogeneity regarding the methodological designs, power of study population, and clinical outcomes [27] [28] [29] [30] [31] (Table 1) . Figure 1 ). Currently, the major problem encountered when comparing the same therapeutic intervention across studies is the lack of consistency in the outcome parameters employed. In a position paper by the EAACI, the unmet need for the harmonization of clinical endpoints in AIT trials was highly emphasized. 33 It is also important to note that some patients do not respond optimally to a treatment due to the complex interaction between patient factors, allergy triggers, symptomatology, and vaccines used for AIT. Thus far, there are no validated or generally accepted candidate biomarkers that may predict and monitor the clinical response to AIT to eventually realize personalized therapy. 5 A recent international consensus paper also highlighted the need for quantitative and validated measurements for potential biomarkers in allergic rhinoconjunctivitis (ARC)( 35 see also "Section 6").
The safety of AIT is another key point that clinical practice focuses on. In general, AIT has good safety and tolerability, but fatal anaphylaxis does occur, and safety can be improved. The safety profile can be assessed by the incidence rates of adverse reactions (AEs).
Adverse reactions in SCIT mostly appear within 30 minutes after the injection and are mainly found to be local reactions, such as pruritus, redness, and swelling at the application site. However, systemic reactions (SRs) such as cough, dyspnea, asthma, rhinoconjunctivitis, and eczema have also been reported. 21 In an Italian 10-year retrospective analysis of more than 2200 patients, 115 SRs to SCIT were found in 5.2% of the treated patients. 36 A more recent survey by the American Academy of Allergy and Clinical Immunology (AAAAI)
reported that the rate of SRs to SCIT was 1.9% of patients, of whom 0.08% and 0.02% experienced grades 3 and 4 AEs, respectively. 37 In a recent meta-analysis, the prevalence of systemic AEs was reported as 7.32% with SCIT. 38 Severe SRs, such as anaphylaxis, are rare, 39 and fatalities have been reported to be decreasing. 37 While the prevalence of SRs to SCIT in AR has been reported to be 23 per AIT, allergen immunotherapy; CS, combined score; HDM, house dust mite; mo, month; MS, medication score; QoL, quality of life; SCIT, subcutaneous immunotherapy; SLIT, sublingual immunotherapy; SS, symptom score; TCRS, total combined rhinitis score; wk, week; y, year.
10 000 injections, or 0.2%, 40 the prevalence of adverse SRs to SCIT in pediatric asthma ranges from 6% to 17% of patients or 0.7 to 1.1 events per patient. 41 In contrast, SLIT represents a viable alternative with a favorable safety profile. 22 In a large trial of 1500 patients receiving SLIT, the incidence of local reactions was reported to be as high as 79%, and they involved oral pruritus, mouth edema, throat irritation, and ear pruritus. 42 These local reactions were generally mild or moderate, occurred during the first week of treatment 43 and decreased over time to 0.35-5.2 events per patient. 41 On the other hand, a 0.056% systemic allergic reaction rate was demonstrated per SLIT dose. 44 However, the incidence of asthma exacerbations was similar in the SLIT group (3.7%) and the placebo group (4.3%) in another trial in house dust mite allergic patients with mild-to-moderate persistent asthma. 45 Furthermore, severe anaphylactic events are very uncommon. 46, 47 Severe SRs from off-label SLIT use occurred in 1.4% of patients, with 0.03% experiencing grade 3 AEs and none experiencing grade 4 AEs. 37 Currently, in AIT practice, age, asthma, allergen dose and content, and sensitization patterns have been considered potential risk factors for AEs with immunotherapy. A higher rate of SRs to SCIT in AR, specifically grade 1 and 2 SRs, was demonstrated in children than in adults. 40 While asthma is considered a risk factor for both systemic reactions and application-site reactions in ARC patients receiving AIT, 17 no increase in systemic allergic reactions or severe local allergic swellings to SLIT was noted in ARC subjects with wellcontrolled mild asthma versus subjects without asthma. 42 New approaches in vaccine technology aim to increase efficacy and tolerability by chemical modification of the allergen, recombinant modification, the administration of peptides, and the use of adjuvants. 5, 25, 48, 49 Recently, a series of clinical trials assessing a novel subcutaneous AIT formulation containing Lolium perenne peptides (LPP) has been reported and showed satisfying clinical efficacies and safety profiles. [50] [51] [52] Compared with whole pollen antigens, LPP are unlikely to cross-link high-affinity IgE receptors and cause allergic reactions, although LPP are administered at higher doses. 50 In addition, continuous overlapping peptides 53 and recombinant B-cell epitopes 54 have also been reported to be safe and well-tolerated in AIT.
Different patterns of sensitization may also potentially be considered a risk factor for the development of AEs to AIT, particularly because a significant association has been demonstrated between the number of grass allergens that sensitized the patients and the total number of AEs reported during the build-up phase of immunotherapy. 
| EAACI GUID ELINES FOR AIT: FROM EVIDENCE TO CLINICAL RECOMMENDATIONS
In recent years, the EAACI has published several systematic reviews on AIT in different indications, such as ARC, 30 allergic asthma, 29 allergy prevention, 31 food allergy, 28 and venom. 27 These systematic reviews were the basis for several clinical AIT guidelines that used the Appraisal of Guidelines for Research and Evaluation (AGREE II) approach, which encompasses the involvement of relevant stakeholders in the field, a standardized search and selection of the relevant literature, a systematic approach to the formulation of clinical recommendations, and strategies to minimize the risk of bias within these procedures. 15 The guidelines aimed to provide evidence-based clinical recommendations for AIT in line with the Oxford Centre for Evidence-based Medicine methodology. 63 Table 3 provides an overview of the key points of each systematic review and guideline. 15 In fact, all guidelines highlight that there are no generic class effects in AIT (neither for formulations nor for application routes); therefore, a product-specific evaluation of efficacy report in the clinical documentation of each AIT product is highly recommended. 16, 17, 64 The guideline for the German-speaking countries (Germany, Austria, and Switzerland) 16 provides Internet-based tables with product-specific evaluations regarding the efficacy, marketing authorization, and status of clinical development programs that can be accessed without further registration and that aim to give a broader (comparative)
overview of different AIT products on the market. 65 In the future implementation of the EAACI guidelines, a similar product-specific approach should be followed on the (European) national level. In addition, several other demands of the AIT guidelines should be implemented. 66 Financial reimbursement tends to be an important "AIT is effective in improving symptom, medication, and combined symptom and medication scores in patients with allergic rhinoconjunctivitis while on treatment, and there is some evidence suggesting that these benefits are maintained in relation to symptom scores after discontinuation of therapy."
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"AIT should be considered in patients with allergic rhinitis (AR), with or without conjunctivitis; evidence of IgE-sensitization to 1 or more clinically relevant allergens; and moderate to severe symptoms despite regular and/or avoidance strategies. An individual product-based evaluation of evidence for efficacy is recommended before treatment with a specific product is initiated. The following can be recommended for AR for shortterm benefit:
• Continuous SCIT for seasonal (Grade A for adults, B for children) or perennial (Grade B for adults, C for children) allergens.
• Pre-and pre-/coseasonal SCIT (Grade A for adults, B for children).
• Modified (allergoids) and unmodified allergen SCIT extracts (Grade A for adults, B for children).
• SLIT aqueous solutions for grass and tree pollens (Grade B for adults, A in children).The following can be recommended for AR for short-and long-term benefits: • Continuous grass pollen SCIT (Grade A for adults, B for children).
• Continuous grass pollen SLIT-tablets or SLIT solution (Grade A).
• HDM SLIT-tablet (but not aqueous solution) for shortterm (Grade A) and long-term benefits (Grade B for adults, C for children). To achieve long-term efficacy, it is recommended that a minimum of 3 years of therapy is used (Grade A).
SCIT and initial SLIT dosage should be administered by competent staff with patients waiting in the clinic for at least 30 minutes after dose (Grade C Europe. 78 These definitions were presented for "pollen season,"
"high pollen season" (or "peak pollen period"), and "high pollen 
| PATH TOWARD PRECISION MEDICINE IN AIT
Precision medicine is a medical model aiming to deliver customized health care, for example, medical decisions, practices, and/or products tailored to the individual patient. 81 AIT is tailored to the specific IgE repertoire responsible for the allergic disease of an individual and modifies the immunological response of that patient, as such AIT is considered a prototype of Precision Medicine in VIT is also recommended to reduce systemic allergic reactions in adults with skin symptoms only when quality of life is impaired (Grade A). VIT is safe for patients with special conditions, such as mastocytosis (Grade C). Pretreatment with H1 antihistamines should be used to prevent large local reactions (Grade A). A 12-week maintenance injection interval can be recommended in lifelong VIT (Grade C).
A 200 μg maintenance dose should be used for patients still reacting while on a conventional (100 μg) dose (Grade C). Lifelong VIT can be recommended in patients at high risk of relapse (Grade C). Considerable gaps were identified in the evidence base emphasizing the need for future well-designed studies, particularly in the pediatric population." | 2283 Allergology 5,81,82 although it still carries some risk, for example, anaphylaxis. 83 Precise information and biomarkers help identify the causes, stratify the eligible patients, and monitor the efficacy and disease control of individual patients supported by e-health and clinical decision support systems (CDSS). The most important biomarkers in type-1 allergies are IgE antibodies, which are used to diagnose allergic type-1 diseases and atopy, but these antibodies are also a major contributor to atopic diseases. 35 For approximately 50 years, serological tests for allergenspecific IgE antibodies have been used to identify the triggers of IgE-mediated allergic symptoms, and the importance of these tests is even increasing due to the potential of molecular componentresolved diagnosis (CRD), especially since skin test allergens may become less available than CRD reagents. 85 CRD comprises a growing spectrum of molecules representing single allergens of clinical relevance that are characterized and produced for commercial in vitro assays, allowing the detailed molecular profiling of the polyclonal IgE repertoire of allergic patients. 86 CRD using allergen molecules instead of extracts may improve test properties by increasing the analytical test sensitivity since important allergen molecules may be underrepresented or lacking in the extract. 86 Additionally, test selectivity or analytical specificity can provide more information on possible cross-reactivity or species-specific reactivity and thus even provide information on risk factors. 86 CRD-IgE tests are thus considered to allow more precise diagnoses before starting AIT in polysensitized patients. 87 Here, molecular CRD testing can help to detect false-positive polysensitizations that may be interpreted as allergen-specific IgE antibodies crossreacting with other molecules.
Consequently, polysensitized patients may be suitable for AIT with standard registered and marketed subcutaneous and/or sublingual AIT products instead of patient-tailored allergen extract mixtures. 88, 89 Monocomponent products of pharmaceutical quality for AIT impact the AIT market in general, and the market share of patient-tailored products with allergenic mixtures can be expected to shrink. 89 Compounding by allergists or allergen manufacturers will be reserved for a limited number of patients with several independent allergies. 89 As AIT targets specific allergens, identifying the disease-eliciting allergen is a prerequisite for an accurate prescription for treatment.
In areas of complex sensitization to aeroallergens or in cases of Hymenoptera venom allergy, the use of molecular diagnostics 90 may lead to a change in the indication and selection of allergens for immunotherapy for a large proportion of patients when compared with the use of skin prick testing and/or specific IgE determination with commercial extracts.
These changes in the AIT prescription landscape aided by molecular diagnosis have been demonstrated to be cost-effective in some scenarios. 91 Certain patterns of sensitization to grass or olive pollen and bee allergens may identify patients with a higher risk of adverse reactions during immunotherapy.
Properly used allergy diagnostics 92 can help clinicians better selecting the most appropriate patients and allergens for AIT and, in some cases, predicting the risk of adverse reactions. The pattern of sensitization to allergens could potentially predict the efficacy of allergen immunotherapy provided that these immunotherapy products contain a sufficient amount of the allergens. Nevertheless, the multiplex assay remains a third-level approach and is not used as a screening method in current practice.
CRD is pushing Allergology into the era of Precision Medicine, an approach integrating individual genetic or molecular data for improved geno-/phenotyping and selection of personal treatments. 93 Accordingly, the need to learn to handle and interpret "allergomic" data is a true challenge for the practicing allergist. 94 Several databases of allergenic molecules and advanced Internet platforms are already available for this purpose. 95 The costs of using cloned or purified allergenic molecules are higher compared with those of extract-based tests; microarrays for detecting multiple allergenic molecules at once will produce even higher costs that need to be balanced against the scarce resources of public health systems. [96] [97] [98] The special AIT indication of insect venom allergy with anaphylactic sting reactions is a good example where molecular allergen detection can contribute to efficiently identifying genuine sensitizations to culprit venom and co-and/or cross-sensitization to different insect venoms. 99 After precisely identifying the molecular antigen to which the patient is allergic, AIT may be performed using a recombinant or even hypoallergenic protein or peptide. Serum IgE reactivity provides information about the concentration of IgE antibodies specific to allergens but not the individual allergenic activity of the measured specific IgE antibodies. As basophil activity depends on both reactivity and sensitivity, BAT with molecular allergens identifies not only the allergen the patient is IgE sensitized to but also the allergenic activity of the specific IgE antibodies. 101 As other allergen challenge procedures, 33 105 To fulfill these conditions, NAC requires a broad spectrum of well-standardized diagnostic test allergens of high quality and even molecular allergens. for its routine use, and no authorized allergen extracts are commercially available for this application route. 110, 112 Epicutaneous immunotherapy is based on the high density of specialized antigen-presenting Langerhans cells in the epidermis that load with antigen to produce very effective immune activation. Since the epidermis is not vascularized, the risk of systemic adverse events is lower in EIT than in AIT. 113, 114 Although epicutaneous or transcutaneous immunization has long been considered an alternative method to conventional vaccination, 115 it took until 2009 to perform a DBPC EIT study using inhalational allergens in this application route. 113 EIT is barely invasive and basically consists of applying 6 patches over a period of 6 weeks, but there is still not enough evi- 125, 126 VLPs loaded with DNA rich in nonmethylated CG motifs (CpGs) were reported to be clinically effective in the treatment of allergic rhinitis. 127 In addition, the use of the VLP technology platform with another adjuvant (MCT) in an "adjuvant systems"
approach is now underway. 
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